Literature DB >> 18084757

Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis.

Hiroshi Ohira1, Ichizo Tsujino, Shinji Ishimaru, Noriko Oyama, Toshiki Takei, Eriko Tsukamoto, Masatake Miura, Shinji Sakaue, Nagara Tamaki, Masaharu Nishimura.   

Abstract

PURPOSE: Despite accumulating reports on the clinical value of (18)F-fluoro-2-deoxyglucose positron emission tomography (18F-FDG PET) and magnetic resonance imaging (MRI) in the assessment of cardiac sarcoidosis, no studies have systematically compared the images of these modalities.
METHODS: Twenty-one consecutive patients with suspected cardiac sarcoidosis underwent cardiac examinations that included 18F-FDG PET and MRI. The association of 18F-FDG PET and MRI findings with blood sampling data such as serum angiotensin converting enzyme levels was also evaluated.
RESULTS: Eight of 21 patients were diagnosed as having cardiac sarcoidosis according to the Japanese Ministry of Health and Welfare Guidelines for Diagnosing Cardiac Sarcoidosis. Sensitivity and specificity for diagnosing cardiac sarcoidosis were 87.5 and 38.5%, respectively, for 18F-FDG PET, and 75 and 76.9%, respectively, for MRI. When the 18F-FDG PET and MRI images were compared, 16 of 21 patients showed positive findings in one (n = 8) or both (n = 8) of the two modalities. In eight patients with positive findings on both images, the distribution of the findings differed among all eight cases. The presence of positive findings on 18F-FDG PET was associated with elevated serum angiotensin-converting enzyme levels; this association was not demonstrated on MRI.
CONCLUSIONS: Both 18F-FDG PET and MRI provided high sensitivity for diagnosing cardiac sarcoidosis in patients with suspected cardiac involvement, but the specificity of (18)F-FDG PET was not as high as previously reported. The different distributions of the findings in the two modalities suggest the potential of 18F-FDG PET and MRI in detecting different pathological processes in the heart.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18084757     DOI: 10.1007/s00259-007-0650-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  40 in total

1.  A unique presentation of cardiac sarcoidosis.

Authors:  Gregg M Slater; E Rene Rodriguez; João A C Lima; David A Bluemke
Journal:  AJR Am J Roentgenol       Date:  2003-06       Impact factor: 3.959

2.  Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis.

Authors:  Shinji Ishimaru; Ichizo Tsujino; Shinji Sakaue; Noriko Oyama; Toshiki Takei; Eriko Tsukamoto; Nagara Tamaki; Masaharu Nishimura
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2005-10       Impact factor: 0.670

Review 3.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms.

Authors:  N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger
Journal:  J Am Soc Echocardiogr       Date:  1989 Sep-Oct       Impact factor: 5.251

4.  Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: comparison with stress thallium imaging.

Authors:  N Tamaki; M Kawamoto; N Takahashi; Y Yonekura; Y Magata; R Nohara; H Kambara; S Sasayama; K Hirata; T Ban
Journal:  J Am Coll Cardiol       Date:  1993-11-15       Impact factor: 24.094

Review 5.  Myocardial sarcoidosis.

Authors:  O P Sharma; A Maheshwari; K Thaker
Journal:  Chest       Date:  1993-01       Impact factor: 9.410

6.  Artifactual inhomogeneities in myocardial PET and SPECT scans in normal subjects.

Authors:  M L Bartlett; S L Bacharach; L M Voipio-Pulkki; V Dilsizian
Journal:  J Nucl Med       Date:  1995-02       Impact factor: 10.057

7.  Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function.

Authors:  R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd
Journal:  Circulation       Date:  1999-11-09       Impact factor: 29.690

8.  Cardiac sarcoidosis. Diagnosis with endomyocardial biopsy and treatment with corticosteroids.

Authors:  B Lorell; E L Alderman; J W Mason
Journal:  Am J Cardiol       Date:  1978-07       Impact factor: 2.778

9.  Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.

Authors:  K J Silverman; G M Hutchins; B H Bulkley
Journal:  Circulation       Date:  1978-12       Impact factor: 29.690

10.  Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis.

Authors:  T Suzuki; T Kanda; S Kubota; S Imai; K Murata
Journal:  Chest       Date:  1994-10       Impact factor: 9.410

View more
  89 in total

1.  Diagnosis and monitoring of cardiac sarcoidosis with delayed-enhanced MRI and 18F-FDG PET-CT.

Authors:  Robert Matthews; Travis Bench; Hong Meng; Dinko Franceschi; Nand Relan; David L Brown
Journal:  J Nucl Cardiol       Date:  2012-08       Impact factor: 5.952

2.  Incidence of abnormal positron emission tomography in patients with unexplained cardiomyopathy and ventricular arrhythmias: The potential role of occult inflammation in arrhythmogenesis.

Authors:  Roderick Tung; Brenton Bauer; Heinrich Schelbert; Joseph P Lynch; Martin Auerbach; Pawan Gupta; Christiaan Schiepers; Samantha Chan; Julie Ferris; Martin Barrio; Olujimi Ajijola; Jason Bradfield; Kalyanam Shivkumar
Journal:  Heart Rhythm       Date:  2015-08-10       Impact factor: 6.343

3.  Advanced cardiovascular imaging for the evaluation of cardiac sarcoidosis.

Authors:  Paco E Bravo; Amitoj Singh; Marcelo F Di Carli; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2018-11-02       Impact factor: 5.952

4.  Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping.

Authors:  Elliott D Crouser; Chikako Ono; Tam Tran; Xin He; Subha V Raman
Journal:  Am J Respir Crit Care Med       Date:  2014-01-01       Impact factor: 21.405

5.  Fasting FDG PET compared to MPI SPECT in cardiac sarcoidosis.

Authors:  Scott C Brancato; James A Arrighi
Journal:  J Nucl Cardiol       Date:  2011-04       Impact factor: 5.952

Review 6.  Recommendations for 18F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations.

Authors:  Shinichiro Kumita; Keiichiro Yoshinaga; Masao Miyagawa; Mitsuru Momose; Keisuke Kiso; Tokuo Kasai; Masanao Naya
Journal:  J Nucl Cardiol       Date:  2019-08       Impact factor: 5.952

7.  Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.

Authors:  Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2017-10       Impact factor: 5.952

Review 8.  Dilated cardiomyopathy with conduction disease and arrhythmia.

Authors:  Neal K Lakdawala; Michael M Givertz
Journal:  Circulation       Date:  2010-08-03       Impact factor: 29.690

9.  Elevated (18)F-fluorodeoxyglucose uptake in the interventricular septum is associated with atrioventricular block in patients with suspected cardiac involvement sarcoidosis.

Authors:  Osamu Manabe; Hiroshi Ohira; Keiichiro Yoshinaga; Takahiro Sato; Alisa Klaipetch; Noriko Oyama-Manabe; Yoichi M Ito; Ichizo Tsujino; Masaharu Nishimura; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-29       Impact factor: 9.236

Review 10.  Role of Cardiac PET in Clinical Practice.

Authors:  Brian M Salata; Parmanand Singh
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.